U.S. markets open in 7 hours 24 minutes
  • S&P Futures

    4,515.50
    -12.50 (-0.28%)
     
  • Dow Futures

    35,391.00
    -86.00 (-0.24%)
     
  • Nasdaq Futures

    15,321.75
    -55.75 (-0.36%)
     
  • Russell 2000 Futures

    2,279.60
    -7.90 (-0.35%)
     
  • Crude Oil

    84.25
    +0.38 (+0.45%)
     
  • Gold

    1,785.80
    +0.90 (+0.05%)
     
  • Silver

    24.42
    -0.02 (-0.08%)
     
  • EUR/USD

    1.1656
    +0.0004 (+0.03%)
     
  • 10-Yr Bond

    1.6360
    0.0000 (0.00%)
     
  • Vix

    15.49
    -0.21 (-1.34%)
     
  • GBP/USD

    1.3813
    -0.0013 (-0.09%)
     
  • USD/JPY

    114.0500
    -0.2790 (-0.24%)
     
  • BTC-USD

    64,917.77
    +1,093.46 (+1.71%)
     
  • CMC Crypto 200

    1,534.63
    +53.83 (+3.64%)
     
  • FTSE 100

    7,223.10
    +5.57 (+0.08%)
     
  • Nikkei 225

    28,702.81
    -552.74 (-1.89%)
     

Akero Therapeutics New Analyses For Efruxifermin Shows Rapid, Substantial Liver Fat Reduction In NASH Patients

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Akero Therapeutics Inc (NASDAQ: AKRO) has announced additional analyses from its Phase 2a BALANCED study of efruxifermin (EFX) in non-alcoholic steatohepatitis (NASH) patients with F1-F3 fibrosis.

  • Data were presented at the 2021 International Liver Congress.

  • These analyses show significant correlations between normalization of liver fat and improvements in markers of liver injury and fibrosis, as well as whole-body metabolism.

  • The new analyses also show that combining ALT response of more than 17 U/L with normalization of liver fat increases the power to predict resolution of NASH.

  • More than 50% reduction in liver fat content was observed in 69% of the patients in the 28mg EFX group, 100% patients in the 50mg EFX arm, and 93% in the 70mg EFX group at week 12.

  • Over 70% liver fat reduction was seen in 50%, 53%, and 80% of the patients in the three dose groups.

  • Only 5% of the patients achieved a liver fat reduction of over 50% or 70% in the placebo arm.

  • Normalization of liver fat content was reported in 25%, 53%, and 67% of the patients in the three dose groups.

  • EFX is currently being evaluated in a Phase 2b HARMONY trial in F2/F3 fibrosis patients.

  • A second Phase 2b trial in patients with Cirrhotic (F4) NASH is planned for the second half of 2021.

  • Price Action: AKRO shares are down 0.65% at $29.76 on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.